NO972494L - Nye pinnsvin-avledede polypeptider - Google Patents

Nye pinnsvin-avledede polypeptider

Info

Publication number
NO972494L
NO972494L NO972494A NO972494A NO972494L NO 972494 L NO972494 L NO 972494L NO 972494 A NO972494 A NO 972494A NO 972494 A NO972494 A NO 972494A NO 972494 L NO972494 L NO 972494L
Authority
NO
Norway
Prior art keywords
derived polypeptides
novel hedgehog
hedgehog
novel
polypeptides
Prior art date
Application number
NO972494A
Other languages
English (en)
Other versions
NO323079B1 (no
NO972494D0 (no
Inventor
Philip A Beachy
Randall T Moon
Jeffey A Porter
Original Assignee
Univ Johns Hopkins Med
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med, Univ Washington filed Critical Univ Johns Hopkins Med
Publication of NO972494D0 publication Critical patent/NO972494D0/no
Publication of NO972494L publication Critical patent/NO972494L/no
Publication of NO323079B1 publication Critical patent/NO323079B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/60—New or modified breeds of invertebrates
    • A01K67/61—Genetically modified invertebrates, e.g. transgenic or polyploid
    • A01K67/65—Genetically modified arthropods
    • A01K67/68—Genetically modified insects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/40—Fish
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/50—Amphibians, e.g. Xenopus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/70—Invertebrates
    • A01K2227/706—Insects, e.g. Drosophila melanogaster, medfly
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Insects & Arthropods (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
NO19972494A 1994-12-02 1997-05-30 Nye hedgehog-avledede rensende polypeptider, isolert polynukleotid, rekombinant ekspresjonsvektor, vertscelle, antistoff, farmasoytisk blanding og autoproteolytisk fusjonsprotein samt fremstilling derav. NO323079B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/349,498 US6281332B1 (en) 1994-12-02 1994-12-02 Hedgehog-derived polypeptides
PCT/US1995/015923 WO1996016668A1 (en) 1994-12-02 1995-12-04 Novel hedgehog-derived polypeptides

Publications (3)

Publication Number Publication Date
NO972494D0 NO972494D0 (no) 1997-05-30
NO972494L true NO972494L (no) 1997-07-30
NO323079B1 NO323079B1 (no) 2006-12-27

Family

ID=23372653

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19972494A NO323079B1 (no) 1994-12-02 1997-05-30 Nye hedgehog-avledede rensende polypeptider, isolert polynukleotid, rekombinant ekspresjonsvektor, vertscelle, antistoff, farmasoytisk blanding og autoproteolytisk fusjonsprotein samt fremstilling derav.

Country Status (9)

Country Link
US (2) US6281332B1 (no)
EP (1) EP0793502A4 (no)
JP (2) JPH11500605A (no)
KR (2) KR20040064700A (no)
AU (2) AU4370596A (no)
CA (1) CA2206509C (no)
FI (1) FI121366B (no)
NO (1) NO323079B1 (no)
WO (2) WO1996017924A2 (no)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165747A (en) * 1993-12-30 2000-12-26 President & Fellows Of Harvard College Nucleic acids encoding hedgehog proteins
JPH09509574A (ja) 1994-02-25 1997-09-30 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 脊索によって発現されるヘッジホッグ、Ｖｈｈ−１、の脊椎動物相同体をコードするＤＮＡ、及びこれらの使用
US6911528B1 (en) 1994-12-02 2005-06-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
IL128999A0 (en) 1996-09-20 2000-02-17 Harvard College Hedgehog interacting proteins and uses related thereto
CA2267106A1 (en) * 1996-10-07 1998-07-16 The Johns Hopkins University School Of Medicine Novel hedgehog-derived polypeptides
DE69841320D1 (de) 1997-02-10 2010-01-07 Harvard College Verfahren zur modulation von hämatopoese und vaskulärem wachstum
AU8173098A (en) 1997-06-27 1999-01-19 Ontogeny, Inc. Neuroprotective methods and reagents
US7144997B2 (en) 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
EP1009424A2 (en) * 1997-08-29 2000-06-21 Ontogeny, Inc. Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6639051B2 (en) * 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
WO1999028454A1 (en) * 1997-11-28 1999-06-10 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
EP0919618A1 (de) * 1997-11-28 1999-06-02 Boehringer Mannheim Gmbh Aktive Hedgehog-Protein-Mutante, Verfahren zur Herstellung und Verwendung
PT1036092E (pt) * 1997-12-03 2005-09-30 Biogen Inc Compos~icoes e metodos de proteinas hidrofobicamente modificadas
US6897297B1 (en) 1997-12-03 2005-05-24 Curis, Inc. Hydrophobically-modified protein compositions and methods
AU1902999A (en) * 1997-12-03 1999-06-16 Biogen, Inc. Hydrophobically-modified protein compositions and methods
US6004937A (en) * 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
ES2252886T3 (es) 1998-04-30 2006-05-16 Curis, Inc. Conjugado de proteinas de erizo activo, proceso para su produccion y uso.
JP2002524528A (ja) 1998-09-11 2002-08-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ ヘッジホッグ様ポリペプチドによる肺組織の調節、およびそれに関する製剤および使用方法
AU773044B2 (en) * 1998-09-11 2004-05-13 Curis, Inc. Hedgehog and patched antagonists for inhibiting cell and tissue growth and differentiation and uses therefor
US6159950A (en) * 1998-10-16 2000-12-12 Cornell Research Foundation, Inc. Method of modulating hair growth
US6884770B1 (en) 1998-11-06 2005-04-26 Curis, Inc. Methods and compositions for treating or preventing peripheral neuropathies
EP1135411B1 (en) * 1998-12-03 2006-05-17 Curis, Inc. Methods and compositions for treating disorders involving excitotoxicity
US8168178B2 (en) 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6683108B1 (en) 2000-03-30 2004-01-27 Curis, Inc. Agonists of hedgehog signaling pathways and uses related thereto
US6613798B1 (en) 2000-03-30 2003-09-02 Curis, Inc. Small organic molecule regulators of cell proliferation
US8852937B2 (en) 2000-03-30 2014-10-07 Curis, Inc. Small organic molecule regulators of cell proliferation
US6683192B2 (en) * 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
AU7549501A (en) * 2000-06-16 2002-01-02 Biogen Inc Angiogenesis-modulating compositions and uses
AU2001296965A1 (en) * 2000-09-22 2002-04-02 The Johns Hopkins University School Of Medicine A method of use of sonic hedgehog protein as a ligand for patched
US6902881B2 (en) 2000-10-13 2005-06-07 President And Fellows Of Harvard College Compounds and methods for regulating cell differentiation
US6908732B2 (en) 2000-10-13 2005-06-21 President & Fellows Of Harvard College Compounds and methods for regulating cell differentiation
US20040060568A1 (en) 2000-10-13 2004-04-01 Henryk Dudek Hedgehog antagonists, methods and uses related thereto
US7708998B2 (en) 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
US7226587B2 (en) 2001-06-01 2007-06-05 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US20040091857A1 (en) * 2001-07-20 2004-05-13 Nallur Girish N. Gene expression profiling
US7160725B2 (en) * 2001-11-13 2007-01-09 Curis, Inc. Hedgehog signaling promotes the formation of three dimensional cartilage matrices
US7553619B2 (en) 2002-02-08 2009-06-30 Qiagen Gmbh Detection method using dissociated rolling circle amplification
EP1496905B1 (en) 2002-04-22 2008-08-13 Johns Hopkins University School of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
RU2323942C2 (ru) * 2002-08-19 2008-05-10 Мерк Патент Гмбх ВАРИАНТЫ ОСНОВНОГО АЛЛЕРГЕНА Phl p 1 ИЗ ТИМОФЕЕВКИ ЛУГОВОЙ
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
US6977153B2 (en) 2002-12-31 2005-12-20 Qiagen Gmbh Rolling circle amplification of RNA
WO2004087870A2 (en) * 2003-03-25 2004-10-14 The Johns Hopkins University Neuronal cell lineages and methods of production thereof
US8043834B2 (en) 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
CA2521623C (en) 2003-04-11 2015-03-17 Etex Corporation Osteoinductive bone material
US20040248103A1 (en) * 2003-06-04 2004-12-09 Feaver William John Proximity-mediated rolling circle amplification
JP5392981B2 (ja) 2003-09-12 2014-01-22 ワイス・エルエルシー 骨形成蛋白の送達のための注入可能なリン酸カルシウム固体ロッドおよびペースト
WO2005097207A2 (en) 2004-03-26 2005-10-20 Curis, Inc. Rna interference modulators of hedgehog signaling and uses thereof
US8410246B2 (en) 2004-06-17 2013-04-02 Thrasos, Inc. TDF-related compounds and analogs thereof
AU2005280112B2 (en) 2004-08-27 2012-07-19 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
US8309303B2 (en) 2005-04-01 2012-11-13 Qiagen Gmbh Reverse transcription and amplification of RNA with simultaneous degradation of DNA
MX2008000985A (es) * 2005-07-21 2008-04-07 Abbott Lab Expresion de gen multiple que incluye construcciones y metodos sorf (cuadro de lectura abierta simple) con poliproteinas, pro-proteinas y proteolisis.
CA2619889C (en) 2005-08-22 2020-05-05 The Johns Hopkins University Use of itraconazole and salts thereof for treating cancer
EP1762627A1 (de) 2005-09-09 2007-03-14 Qiagen GmbH Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
DK2497780T3 (en) 2005-09-20 2015-06-01 Thrasos Innovation Inc TDF-related compounds and analogs thereof
WO2007054623A2 (en) * 2005-11-11 2007-05-18 Licentia Oy Mammalian hedgehog signaling inhiabitors
WO2007067514A2 (en) * 2005-12-05 2007-06-14 Boston Biomedical Research Institute Methods for identifying modulators of hedgehog autoprocessing
US8147860B2 (en) 2005-12-06 2012-04-03 Etex Corporation Porous calcium phosphate bone material
US7625759B2 (en) 2005-12-19 2009-12-01 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
ES2443581T3 (es) 2006-02-09 2014-02-19 Biomimetic Therapeutics, Llc Composiciones y métodos para el tratamiento de hueso
AU2007243946B2 (en) 2006-04-05 2012-11-29 Curis, Inc. Method for using BOC/CDO to modulate hedgehog signaling
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
AU2007269712B2 (en) 2006-06-30 2013-02-07 Biomimetic Therapeutics, Llc PDGF-biomatrix compositions and methods for treating rotator cuff injuries
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
RU2009137012A (ru) 2007-03-07 2011-04-20 Инфинити Дискавери, Инк. (Us) Аналоги циклопаминлактама и способы их применения
JP2010520295A (ja) 2007-03-07 2010-06-10 インフィニティ・ディスカバリー・インコーポレイテッド へテロ環状シクロパミン類似体及びその使用方法
US20090061002A1 (en) 2007-09-05 2009-03-05 Venbrocks Rudolf A Calcium phospate based delivery of growth and differentiation factors to compromised bone
CA2710858A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
BR122020000059B8 (pt) 2008-09-09 2021-06-22 Biomimetic Therapeutics Inc composição que compreende uma matriz biocompatível e um fator de crescimento derivado de plaqueta e kit
AU2010279325B2 (en) 2009-08-05 2016-10-20 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
JP2013503846A (ja) 2009-09-01 2013-02-04 ファイザー・インク ベンズイミダゾール誘導体
BR112012020566B1 (pt) 2010-02-22 2021-09-21 Biomimetic Therapeutics, Llc Composição de fator de crescimento derivado de plaqueta
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CA2813162C (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2- derivatives as smoothened receptor modulators
WO2014012101A1 (en) 2012-07-13 2014-01-16 Trustees Of Tufts College Silk powder compaction for production of constructs with high mechanical strength and stiffness
PL3302428T3 (pl) 2015-06-04 2026-04-13 Sol-Gel Technologies Ltd. Preparaty do zastosowania miejscowego do dostarczania związków inhibitora hedgehog i ich zastosowanie
EP3821880A1 (en) 2015-10-26 2021-05-19 President and Fellows of Harvard College Oxidized polysaccharides and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8611832D0 (en) * 1986-05-15 1986-06-25 Holland I B Polypeptide
US5789543A (en) * 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
EP0741783B1 (en) 1993-12-30 2009-03-18 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins

Also Published As

Publication number Publication date
EP0793502A1 (en) 1997-09-10
WO1996017924A3 (en) 1996-09-26
FI972312A0 (fi) 1997-05-30
KR987000085A (ko) 1998-03-30
JPH11500605A (ja) 1999-01-19
AU4370596A (en) 1996-06-26
WO1996017924A2 (en) 1996-06-13
CA2206509C (en) 2011-05-03
FI121366B (fi) 2010-10-29
CA2206509A1 (en) 1996-06-06
WO1996016668A1 (en) 1996-06-06
US6132728A (en) 2000-10-17
FI972312L (fi) 1997-12-30
NO323079B1 (no) 2006-12-27
AU712346B2 (en) 1999-11-04
EP0793502A4 (en) 1999-10-13
AU4418396A (en) 1996-06-19
KR20040064700A (ko) 2004-07-19
NO972494D0 (no) 1997-05-30
US6281332B1 (en) 2001-08-28
JP2006151989A (ja) 2006-06-15
KR100453096B1 (ko) 2005-04-06

Similar Documents

Publication Publication Date Title
NO972494L (no) Nye pinnsvin-avledede polypeptider
NO970512D0 (no) Nye heteroaryl-oksazolidinoner
NO970374L (no) Nye forbindelser
DK155690D0 (da) Nye peptider
NO950852L (no) Nye forbindelser
FI912086A7 (fi) Polypeptidejä
FI954147L (fi) Polypeptidejä
FI965225L (fi) Uusia peptidejä
DE69535069D1 (de) Vermittlungseinrichtung
NO20001938D0 (no) Nye aryloksy-alkyl-dialkylaminer
NO952650D0 (no) Nye peptider
DK0906288T3 (da) Nye forbindelser
DK0770132T3 (da) Nye streptograminer
NO960268D0 (no) Nye dialkoksypyridinylbenzimidazolderivater
DK158390D0 (da) Nye peptider
DE69534544D1 (de) Vermittlungseinrichtung
DE69522910D1 (de) Abtastschaltung
FI972215L (fi) Uusia polypeptidejä
NO990072D0 (no) Nye forbindelser
NO940195L (no) Nye forbindelser
NO991097D0 (no) Nye fremgangsmÕter
NO983505D0 (no) Nye fenantrider
NO942051D0 (no) Nye tiosemikarbazontioner
SE9502007D0 (sv) Novel polypeptides
NO952939D0 (no) Nye substituerte tiosemikarbazontioner

Legal Events

Date Code Title Description
MK1K Patent expired